Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 5Specimen Handling 4exemestane 2Letrozole 2Anastrozole 2fezolinetant 1elacestrant 1Testosterone 1Surgical Procedures, Operative 1Omacor 1Neoadjuvant Therapy 1FAPI-46 1Biopsy 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Omacor × 30 days × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡